ReviewFrontiers in immunology2022

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review.

Jiayi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.